| EPSRC Reference: |
EP/P02324X/1 |
| Title: |
Multiparameter Assay for Profiling Susceptibility (MAPS) |
| Principal Investigator: |
Krauss, Professor T |
| Other Investigators: |
|
| Researcher Co-Investigators: |
|
| Project Partners: |
|
| Department: |
Physics |
| Organisation: |
University of York |
| Scheme: |
Standard Research |
| Starts: |
01 September 2017 |
Ends: |
31 March 2021 |
Value (£): |
1,127,252
|
| EPSRC Research Topic Classifications: |
| Analytical Science |
Med.Instrument.Device& Equip. |
|
| EPSRC Industrial Sector Classifications: |
|
| Related Grants: |
|
| Panel History: |
| Panel Date | Panel Name | Outcome |
|
06 Feb 2017
|
HIPs 2017 Panel Meeting
|
Announced
|
|
|
Summary on Grant Application Form |
Antimicrobial resistance (AMR) is the ability of microbes to evolve resistance against an antimicrobial treatment. For example, a bacterium can develop resistance to an antibiotic medicine, rendering that medicine ineffective in treating and containing the infection. The loss of effective antibiotics will have a significant impact on our lives, not only increasing the chances of developing a serious infection but also increasing the risk associated with medical procedures. The recent O'Neill review predicts "If we fail to act, we are looking at an almost unthinkable scenario where antibiotics no longer work and we are cast back into the dark ages of medicine".
While AMR in bacteria occurs naturally over time, the misuse and overuse of antibiotics is accelerating this process. For example, many infections such as tonsillitis are predominantly (80%) viral and can thus not be treated with antibiotics, yet antibiotics are still prescribed. An obvious solution is to introduce new drugs. However, this is not only very costly but it is also inevitable that resistance to any new medicine will develop.
A promising and sustainable solution to the AMR problem is the introduction of diagnostic tests that not only confirm a bacterial infection but also identify the best antibiotic for treating the infection. The aim of this project is to develop a diagnostic that will ensure the right drugs are prescribed at the right time. The technology, called MAPS, is based on silicon photonics. Although developed originally for use in the communications industry, we have shown that this same technology can be used to monitor biology, including bacteria and proteins, with very high sensitivity. We will exploit this technology to create a diagnostic that will identify the type of bacterium and severity of infection, the presence of resistance mechanisms and the most promising antibiotic for treatment. Working with clinical and industrial collaborators, we will demonstrate and validate the technology for the treatment of urinary tract infections and determine a route for taking it to the market.
|
|
Key Findings |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
|
Potential use in non-academic contexts |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
|
Impacts |
|
| Description |
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk |
| Summary |
|
| Date Materialised |
|
|
|
|
Sectors submitted by the Researcher |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
| Project URL: |
|
| Further Information: |
|
| Organisation Website: |
http://www.york.ac.uk |